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The opioid epidemic is the most significant modern-day, public health crisis. Physicians and 
lawmakers have developed methods and practices to curb opioid use. This article describes one 
method, prescription drug monitoring programs (PDMP), through the lens of how to optimize use for 
emergency departments (ED). EDs have rapidly become a central location to combat opioid abuse 
and drug diversion. PDMPs can provide emergency physicians with comprehensive prescribing 
information to improve clinical decisions around opioids. However, PDMPs vary tremendously in their 
accessibility and usability in the ED, which limits their effectiveness at the point of care. Problems 
are complicated by varying state-to-state requirements for data availability and accessibility. 
Several potential solutions to improving the utility of PDMPs in EDs include integrating PDMPs with 
electronic health records, implementing unsolicited reporting and prescription context, improving 
PDMP accessibility, data analytics, and expanding the scope of PDMPs. These improvements 
may help improve clinical decision-making for emergency physicians through better data, data 
presentation, and accessibility. [West J Emerg Med. 2018;19(2)387–391.]
INTRODUCTION
Due to the growing opioid epidemic in the U.S., there 
is widespread interest in using prescription drug monitoring 
systems (PDMP) to curb prescription drug abuse. PDMPs 
are statewide databases used by physicians, pharmacists, 
and law enforcement to obtain data about controlled-drug 
prescriptions, with the goal of detecting substance-use 
disorders, drug-seeking behaviors, and reducing patient 
risks of adverse drug events. While almost all U.S. states 
have PDMPs, they vary in design and implementation.1 In 
this paper, we review the history, evidence, and adoption 
of best practice guidelines in state PDMPs with a focus on 
how to best deploy PDMPs in emergency departments (ED). 
Specifically, we analyze the current PDMP model and provide 
recommendations for PDMP developers and EDs to help 
meet the informational needs of ED providers with the goal of 
better detection and prevention of prescription drug abuse.
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THE OPIOID CRISIS AND THE EMERGENCY 
DEPARTMENT
The U.S. accounts for roughly 80% of opioid use 
worldwide, and misuse – such as the recreational use of 
opioids – is a significant problem.2 Every 19 minutes in the 
U.S. someone dies from an unintentional drug overdose, 
the majority from opioids.3 From 1997 to 2007 the average 
milligram (mg)-per-year use of prescription per person of 
opioids in the U.S. increased 402%, from 74 mg to 369 mg. 
Meanwhile, an estimated seven million people above the age 
of 12 use opioids and other prescription medications for non-
therapeutic purposes annually.3,4 These non-medical uses of 
opioids are linked to 700,000 ED visits yearly.3 
Along with treating the consequences of opioid-related 
illness and overdose, EDs are often a location used by some 
patients as a source for opioid prescriptions.4 With limited time 
and no prior patient relationship, emergency physicians (EP) 
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must make quick decisions balancing the provision of sufficient 
pain management against the potential for abuse and/or misuse. 
It is sometimes difficult to detect who might be seeking to 
misuse opioids. In one study, “classic” drug-seeking behaviors 
were relatively ineffective in identifying high-risk patients.3
A Brief History of PDMPs and Their Effectiveness
PDMPs have been available for nearly 80 years. The first 
state PDMP was established in California (1939), followed 
by Hawaii (1943), Illinois (1961), Idaho (1967), New York 
(1970), Pennsylvania (1972), Rhode Island (1978), Texas 
(1981), and Michigan (1988).5 Early PDMPs were paper-based, 
recordkeeping systems used primarily to provide reports to 
law enforcement.5 By 1990 electronic key-punch databases 
enabled easier data dissemination via PDMPs, and pharmacists 
and clinicians began to use them.5 In 1996 the pharmaceutical 
OxyContinTM was introduced; simultaneously, illicit prescription 
drugs doubled from 1994-1998.5 In response, Congress signed 
the Harold Rogers Prescription Monitoring Program grant into 
law in 2002, providing the first guidelines and funding for states 
to develop PDMPs.5 Since then, 49/50 states have now adopted 
PDMPs. (Missouri is the only exception).6 
Since the inception of PDMPs, studies have assessed 
their impact on opioid prescribing and overdoses. Overall, 
the literature has been mixed. Some studies have found no 
relationship between PDMP implementation and outcomes; 
however, most studies evaluated paper- or faxed-based 
systems, with physicians receiving information days to weeks 
after the initial request.4,7 In one such study, 21% of the 
PDMPs evaluated were within their first years of operation or 
had only recently come online.4 This is significant because in 
states with new PDMPs, (Maine, New Mexico and Wyoming 
[which became operational in 2004-2005]), many physicians 
were not accessing or using data.4 This point is exemplified 
through Virginia’s PDMP, which was established in 2007 and 
was initially paper based.8 After moving to electronic and 
real-time reporting, data requests exponentially increased from 
74,342 in 2009 to 433,450 in 2010.8
Another factor limiting the effectiveness of PDMPs is that 
each state has different policies and requirements for providers 
to use them. Few states mandate prescriber use and in those 
states that do not mandate use, compliance varies greatly.7 In 
this context, it is logical to assume that if prescribers do not 
access PDMP data, they cannot be effective.
VARIATION IN PDMP DESIGN AND 
IMPLEMENTATION
A clear factor that leads to variation in observed 
effectiveness is that PDMPs are not all designed in the same 
way, particularly when it comes to their accessibility. Most 
are representative of separate and distinct technological 
and political environments at the time of their creation.5 
According to the National Alliance for Model State Drug 
Laws study in late 2012, 38 state PDMPs are operated by a 
state health agency and six are operated under the aegis of 
law enforcement agencies.9 Additionally, 45 states monitor 
schedule II-IV controlled substances, 34 states grant authority 
to monitor schedule V substances, and 13 allow additional 
monitoring of drugs not listed on Drug Enforcement 
Administration schedules.9 Moreover, while several states 
require physicians to access patient PDMP data before 
prescribing controlled substances, the majority of states allow 
for voluntary participation among physicians.9 Finally, 25 
states provide unsolicited, automatic reports of suspicious 
activity directly to law enforcement but only three (Delaware, 
Louisiana, and West Virginia) automatically send reports 
to multiple facilities including law enforcement, licensing 
boards, pharmacies, and prescribers.9 
However, states have looked to update and reformat their 
PDMPs to better address the opioid crisis. For example, with 
funding from the Core State Violence and Injury Prevention 
Program, Oregon reformatted its PDMP to provide more 
appropriate data to its EPs.10 Under this new funding, PDMPs 
were designed to track schedule II-VI drugs prescribed within 
Oregon as well as providing physicians with access to the 
PDMP data of bordering states.10 Furthermore, pharmacies 
within Oregon were required to report prescription data within 
72 hours of opioid dispensing.10 Such interstate sharing and 
tracking of all scheduled drugs has shown to provide safer 
patient care. Since implementation, Oregon has reported a 
38% decrease in the rate of prescription opioid overdose as 
well as a 58% reduction in deaths related to methadone use.11 
As sharing hubs such as those in Oregon, Michigan, Indiana 
and Ohio are established, EPs may be better equipped to 
successfully identify drug-seeking behavior. 
PDMP design also leads to great variation in usability. For 
example, some information displayed is not always relevant 
or organized in a way that allows for EPs to answer specific 
clinical questions that fit into ED workflow. In some systems, 
frequent extraneous information is obtained simultaneously.2 
Excessive data forces providers to search for relevant 
information, squandering valuable time. 
Furthermore, clinician training on how to use and 
interpret PDMPs is often limited. Users are often left wading 
through mountains of patient data seeking to piece together 
a complete picture. One study surveyed physicians and 
nurses from diverse specialties after PDMP use and found 
that practitioners lacked guidance on data interpretation.12 
In EDs time is a valuable resource and, unfortunately, 
the complexity of some PDMPs limits their usability. For 
example, in the current structure, PDMPs have experienced 
growing compliance issues secondary to their difficulty of 
use. In certain states, physicians are required to register with 
their PDMP via a notarized medical license and government 
identification.13 Password protocols exacerbate issues with 
PDMP accessibility. Often physicians are required to meet 
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excessive requirements for password security only to find that 
within a short time their password has expired and the process 
starts over. Passwords often cannot match previous entries 
and involve multiple erroneous key elements to meet required 
fields. Working in a fast-paced ED, having to frequently create 
and update complicated passwords quickly transforms these 
safeguards into a barrier to use.
Finally, not all PDMPs track all schedule drugs. Schedule 
II drugs such as opioids have largely been the focus of 
PDMPs, but other drugs categorized in alternative schedules 
also have the potential for abuse. In 2011, for example, 
ED visits for benzodiazepine abuse, a schedule IV drug, 
was nearly equal to visits for opioids.14 ED records have 
demonstrated a strong association with benzodiazepine abuse 
and opioid abuse.15 Despite this potential for additional abuse, 
only 34 PDMPs monitor schedule II-V drugs.16 To address 
many of the usability limitations with PDMPs in EDs, we 
suggest several ways to optimize their implementation.
Integration into ED Electronic Health Records
First, working to integrate the PDMPs with electronic health 
records (EHR) is a key to effectively using PDMPs. Currently, 
while clinicians are working in their hospital’s EHR system, most 
have to open a web-browser and log in to a separate, secure page 
with a separate username and password that is often a time-
consuming process, further deterring the widespread use of the 
PDMP data. In the interest of time, physicians instead often resort 
to using prior EHR data to make determinations about possible 
drug seeking. Considering that EHR data is typically not shared 
between facilities, physicians base decisions on significantly 
smaller sample sizes. Indiana became the first state to merge an 
EHR with the PDMP. The integration was found to be highly 
effective with 58% of physicians prescribing fewer opioids 
or smaller quantities after the implementation of the PDMP 
data.17 Furthermore, integration of these systems could allow 
for improvements through unsolicited reporting “alerts” on 
the EHR for accessing physicians.18 These alerts could be used 
much like a “sepsis alert,” indicating a questionable prescription 
history of a patient immediately, allowing clinicians to further 
investigate if needed.18
Unsolicited Reporting
Unsolicited reporting is a powerful tool through which 
PDMPs can automatically send alerts for drug-seeking 
behavior meeting a specific threshold to the appropriate 
authority. Such quantitative thresholds have already been 
implemented in several states with some success. In Virginia, 
thresholds for individuals receiving 10 prescriptions from 
10 providers (10x10) or (15x15) within a six-month period 
were used.19 Subsequent periodic analysis of the data for 
automatic, unsolicited reporting showed a steady decrease in 
the number of individuals meeting thresholds, correlating to 
a decrease in likely diversion and abuse.19 Such automated 
reporting does come with risk as such policies raise concerns 
about patients being labeled an addict or postponing 
necessary treatment.18 In addition, physicians treating cancer 
patients or those requiring long-term opioid management 
have expressed concern for their reputation and licensure.18 
However, in the context of the newly-approved National 
Quality Forum measures for limiting opioid prescribing, 
PDMPs can take such measures into consideration and would 
likely have an inverse effect by ensuring that guidelines are 
followed and patients are treated safely.20
Providing Context for Opioid Prescriptions Through Data 
Analytics
Data analytics and data visualization may be ways to help 
contextualize opioid prescriptions for the busy EP. For example, 
by linking prescriptions to a particular diagnosis physicians may 
greatly reduce the guesswork involved for prescription behavior. 
At a glance, a patient with multiple prescriptions for both short- 
and long-acting, opioid pain medications may appear to be an 
opioid abuser. However, by tethering an explanatory diagnosis 
to such prescriptions, after investigation this patient could be 
found to have an extensive chronic pain condition warranting 
multiple prescriptions. Therefore, fewer mental resources may 
be required to rule out opioid abuse, reducing the potential for 
misinterpreting data and in turn provide quicker and better-
informed emergency care. 
Expanding the Accessibility to PDMPs Within the ED
Another common complaint from attending physicians 
is the restriction allowing use of PDMPs only by licensed 
and practicing attending physicians, and excluding resident 
physicians. By allowing resident physicians access to PDMP 
information, the clinical care team could be more efficient 
particularly in academic settings where residents make many 
clinical decisions. In addition, allowing other providers who 
work in the ED, such as nurses and technicians, access to 
PDMP data may further amplify their effectiveness and use as 
a screening instead of a confirmation tool. 
Expanding the Scope of PDMPs
PDMPs have an extensive capability for tracking drug-
seeking behavior and contacting the appropriate authorities 
such as prescribers, pharmacies, licensing boards or law 
enforcement. However, given that abuse is not limited to 
opioid misuse, but includes benzodiazepines and other 
schedule drugs as well, it is logical to assume that by 
extending PDMP records to include tracking of all scheduled 
drugs, PDMPs can have a greater impact against multiple 
forms of doctor shopping, drug abuse and diversion.
Models of Well-designed PDMPs
Despite the issues highlighted above, some PDMPs 
studies still suggest a positive trend between their use and 
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subsequent decreases in opioid and prescription-drug abuse. 
While opioid prescription overdose and abuse steadily 
increased from 2002-2010, by 2011 opioid prescriptions 
declined and consequently opioid overdose-related deaths 
fell and abuse plateaued.21 As more modern PDMP systems 
came online in conjunction with this decline, they are 
thought to have played a role in by reducing prescriptions 
in circulation and providing local governments with 
better resources to identify illicit activity. Furthermore, in 
Kentucky, Tennessee, New York and Ohio, early adopters 
of mandated PDMP use have shown preliminary results 
significant for a reduction in opioid prescribing as well 
as declines in multiple providers prescribing or in doctor 
shopping.7 Meanwhile, a 2016 study found a reduction on 
average of 1.12 fewer, opioid-related overdose deaths per 
100,000 cases annually by implementing a PDMP program.7 
Finally, another 2016 study showed that from 2003-2009, 
states without PDMPs experienced a steady increase in 
opioid exposures of 1.9% per quarter annually, while states 
with PDMPs in place experienced increases of only 0.2%.2
CONCLUSION
EDs and their providers are on the front lines of 
the opioid crisis, treating significant portions of the 
surrounding community. As a result, their clinical decision-
making has effects throughout their community, and 
improving the effectiveness of the PDMP in the ED has 
the potential to curb drug abuse and diversion. Yet PDMPs 
are currently complicated by myriad different strategies 
with varying state-to-state requirements and a lack of 
interconnectivity, which limit their usability and use. 
Several potential solutions exist to enhance PDMPs in the 
ED including integrating PDMPs with EHRs, implementing 
unsolicited reporting and prescription context, improving 
PDMP accessibility and data analytics, and expanding the 
scope of PDMPs.
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